Interleukin-12 gene therapy - OncoSec Medical

Drug Profile

Interleukin-12 gene therapy - OncoSec Medical

Alternative Names: DNA IL-12; IL-12 gene therapy; ImmunoPulse; ImmunoPulse®IL-12; OMS ElectroImmunotherapy™; pIL-12; pIL-12 Electroporation; Plasmid IL-12

Latest Information Update: 23 Dec 2016

Price : $50

At a glance

  • Originator Inovio Biomedical Corporation
  • Developer Fred Hutchinson Cancer Research Center; Massachusetts General Hospital; OncoSec Medical; University of California at San Francisco; University of Washington
  • Class Cytokine genes; Gene therapies; Immunotherapies; Interleukins
  • Mechanism of Action Gene transference; Immunomodulators; Immunostimulants; Interleukin-12 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Cutaneous T cell lymphoma; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma
  • Preclinical Solid tumours

Most Recent Events

  • 12 Dec 2016 OncoSec completes a phase II trial in Head and neck cancer in USA (Intratumoural) (NCT02345330)
  • 08 Dec 2016 OncoSec Medical plans a phase III registrational trial for Malignant melanoma in USA
  • 19 Jul 2016 Interim efficacy data from a phase II trial in malignant melanoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top